Isis Builds On Platform Strategy With Fourth Biogen Tie-Up
This article was originally published in The Pink Sheet Daily
Executive Summary
The antisense company has made it clear that it will not pursue commercialization of its own drugs, but intends to partner out all of its assets, while still retaining the most advantageous economics. Its fourth agreement with Biogen Idec, a strategic collaboration, is the most extensive and lucrative to date with the partner.
You may also be interested in...
Biopharma Dealmaking Quarterly Statistics, Q3 2013
Biopharma financing in Q3 2013 totaled $4.6 billion, a 58% drop from the second quarter; Perrigo’s $8.3 billion acquisition of Elan made up more than half of the M&A dollar value; and marketed products made up the majority of licensed products.
Deals of the Week Watches Parkinson’s In Prime Time
Biogen Idec strikes a neurodegenerative research deal with Amicus Therapeutics and another antisense deal with Isis. Elsewhere, Merck and AstraZeneca team up in ovarian cancer, Roche obtains rights to two cancer immunotherapies from Inovio, and GSK sells a pair of beloved drinks to a Japanese beverage company.
Deals of the Week Watches Parkinson’s In Prime Time
Biogen Idec strikes a neurodegenerative research deal with Amicus Therapeutics and another antisense deal with Isis. Elsewhere, Merck and AstraZeneca team up in ovarian cancer, Roche obtains rights to two cancer immunotherapies from Inovio, and GSK sells a pair of beloved drinks to a Japanese beverage company.